Loading…
← CockpitCompetitor Analysis › PBLS Parabilis Medicines, Inc.Open in the cockpit ↗

Parabilis Medicines, Inc.PBLSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage cancer drug developer using stabilized helical peptides (Helicons) to reach hard targets inside cells; lead drug zolucatetide blocks beta-catenin.

Mkt cap
$3.52B
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$24.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-88.7 pp
WACC 19.9%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$28.47
1D+0.8%
1W-4.0%
1M+5.1%
3M-28.1%
6Mn/a
YTDn/a
1Yn/a
ATR %7.3%
52w lowhigh33.0% off high

What Parabilis Medicines does

Clinical-stage cancer drug developer using stabilized helical peptides (Helicons) to reach hard targets inside cells; lead drug zolucatetide blocks beta-catenin.

With no approved product, it is funded by investor money and partner payments, chiefly a May 2026 deal with Regeneron on antibody-Helicon conjugates, antibodies that carry a Helicon in place of a toxic payload, with upfront and milestone fees. It listed on Nasdaq in June 2026. Value rests on zolucatetide's desmoid-tumor results.

Products and services

  • Zolucatetide (beta-catenin/TCF inhibitor)
  • ERG degrader (prostate cancer, preclinical)
  • Androgen-receptor AR(ON) degrader (preclinical)
  • Beta-catenin degrader (preclinical)
  • Antibody-Helicon conjugates (Regeneron collaboration)

Customers

  • Patients with desmoid tumors and FAP (future)
  • Regeneron (collaboration partner)

Where it sits in the supply chain

  • Pharmaceuticals
  • Oncology
  • Clinical-stage peptide therapeutics

What could go right

  • Planned Phase 3 start in desmoid tumors
  • Regeneron collaboration milestones

What could go wrong

  • One clinical-stage drug carries the story
  • Trial and regulatory risk in rare tumors

Moat: narrow (IP / patents, process know-how). Proprietary Helicon peptide platform; only one drug in the clinic so far, so the edge is unproven.

Headquarters: Cambridge, Massachusetts, US · Founded: 2015

Named competitors

Parabilis Medicines at a glance

Size Parabilis Medicines (PBLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.52B, the 1425th largest of 3,085 United States companies the cockpit tracks. Shares closed at $28.47 on 18 Nov 2026.

Capital Return on invested capital runs 88.7 points below its cost of capital (19.9% WACC).

Short interest Short interest is 9.1% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Parabilis Medicines financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$2.50M-$2.11M
EBITDAn/a-$150M-$124M
Net incomen/a-$146M-$118M
Free cash flown/a-$124M-$105M
Capital expendituren/a$306,000$879,000
Total debt$41.8M$58.7M$66.2M

Quarterly statements and history in the cockpit →

Parabilis Medicines competitors and peer comparison

Head to head with its named competitors (PBLS vs ARVN vs KYMR vs RVMD)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Parabilis Medicines PBLS$3.52Bn/an/an/an/an/a
Arvinas ARVN$443M-26%-12%-10%n/an/a
Kymera Therapeutics KYMR$10.3B+50%+134%-396%92.4×n/a
Revolution Medicines RVMD$34.6B+6%n/a-853%162.6×n/a
Merck KGaA MRK.DE$71.3B+16%+1%19%3.4×7.4%

How Parabilis Medicines compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Parabilis Medicines against its 20 peers (data as of 18 Nov 2026)
MeasurePBLSPeer medianRank in peer set
1-month return+5.1%+2.6%9th highest of 21
Distance from 52-week high-33.0%-21.3%5th lowest of 21
ROIC minus cost of capital-88.7 pp+4.3 pp2nd lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%8.4×n/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%106.6×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%2.6×-3.4%+10.6%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%3.8×n/an/a
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%2.5×4.7%+4.5%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%2.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%5.2×34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%4.2×1.2%+12.1%

Questions

Who are Parabilis Medicines's main competitors?
Named competitors: Arvinas (ARVN), Kymera Therapeutics (KYMR), Revolution Medicines (RVMD), Merck KGaA (SpringWorks) (MRK.DE). The cockpit's measured peer set (industry) also includes Siegfried (SFZN.SW), Wockhardt (WOCKPHARMA.NS), Acutaas Chemicals (ACUTAAS.NS), Shanghai Junshi Biosciences (1877.HK), Arcutis Biotherapeutics (ARQT), Jiangsu Nhwa Pharmaceutical (002262.SZ).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.